Thursday 7 May, 2026
Introduction ECMO (extracorporeal membrane oxygenation) therapy provides temporary cardiac and/or respiratory support to critically ill patients, and anti-infective agents are…
Read morePoster: Drug/Disease Modelling - Infection
PYRAZINAMIDE POPULATION PHARMACOKINETICS IN ADULTS WITH DRUG-RESISTANT TUBERCULOSIS: THE ROLE OF ALLOMETRIC SCALING
Thursday 7 May, 2026
Objective: Pyrazinamide is a key sterilizing agent in first- and second-line tuberculosis (TB) treatment [1]. Current WHO guidelines recommend weight-band…
Read moreA lesion-centric extension of a minimal PBPK model to predict anti-tuberculosis drug target attainment in rabbits
Thursday 7 May, 2026
Objectives: Tuberculosis (TB), one of the deadliest infectious diseases worldwide [1], still requires therapy optimization to eradicate Mycobacterium tuberculosis residing…
Read moreA pharmacometric model of the in vitro co-dynamics of Staphylococcus aureus and three phage candidates
Thursday 7 May, 2026
Objectives Phage therapy is a promising approach for treating infections caused by multidrug-resistant bacteria such as Staphylococcus aureus (S. aureus)….
Read moreA translational framework for predicting early bactericidal activity of bedaquiline and pretomanid using in vitro time-kill assays
Thursday 7 May, 2026
The authors Pietro Laddomada and Marie Sylvianne Rabodoarivelo contributed equally to this work. Objectives: Phase IIa pulmonary tuberculosis (TB) trials…
Read moreModel-Informed Precision Dosing of Cefepime: A Simulation Study Evaluating Target Attainment and Neurotoxicity Risk
Thursday 7 May, 2026
Introduction: Cefepime is a broad-spectrum beta-lactam antibiotic critical for treating severe gram-negative infections, including Pseudomonas aeruginosa. Optimal dosing requires balancing…
Read moreGLOBAL VARIANCE-BASED SENSITIVITY ANALYSIS OF A PHARMACODYNAMIC MODEL FOR PIPERACILLIN/TAZOBACTAM TOWARDS OPTIMISED DOSING STRATEGIES
Thursday 7 May, 2026
Introduction: The β-lactam/β-lactamase inhibitor combination piperacillin/tazobactam (PIP/TAZ) is a widely used empirical therapy in critical ill patients. The minimum inhibitory…
Read morePOPULATION PHARMACOKINETICS OF DELAMANID AND ITS MAIN METABOLITE DM-6705 IN BREASTMILK IN PATIENTS TREATED FOR RIFAMPICIN-RESISTANT TUBERCULOSIS
Thursday 7 May, 2026
Objectives: Delamanid, a nitroimidazole drug used in the treatment of rifampicin-resistant tuberculosis (RR-TB),[1] has limited pharmacokinetic data describing its distribution…
Read morePopulation pharmacokinetic–based probability of target attainment analysis of cefepime/nacubactam and aztreonam/nacubactam for carbapenem-resistant enterobacterales infections
Thursday 7 May, 2026
Introduction: OP0595 (nacubactam) is a novel β-lactamase inhibitor with dual mechanisms of action: as an inhibitor of serine β-lactamases (classes…
Read moreFOUR-SNP NAT2 GENOTYPING OUTPERFORMS TAG-SNP AND MIXTURE MODELS FOR HIGH-DOSE ISONIAZID PK
Thursday 7 May, 2026
Objectives Isoniazid is used at standard doses of 4–6 mg/kg for drug-susceptible tuberculosis and at higher doses of 10–15 mg/kg…
Read more